Takeda Collaborates with LegoChem Biosciences (LCB) to Develop Antibody-Drug Conjugates in Immuno-Oncology

Shots:

• LCB to receive $7.25M upfront, $404M as regulatory & commercial milestones and royalties on sales of ADCs product. Takeda licenses rights for LCB’s ConjuAll technology including linker and conjugation platform to develop & commercialize targetted immune-oncology therapies for three targets
• The focus of the collaboration is to utilize LCB’s ADC technology including linker and payload platform in multiple oncology & immune-oncology therapies
• LCB’s ConjuAll is ADC technology is a platform providing solutions for site-specific conjugation, linker stability and efficient payload release in the development of ADC, antibiotics, anticoagulants and anticancer therapies

Click here to read full press release/ article | Ref: BusinessWire | Image: TheStreet